{
    "id": "4guwucrdauaqeegdm3n6nnyusdmc4j4e",
    "title": "Modeling drug- and chemical-induced hepatotoxicity with systems biology approaches",
    "info": {
        "author": [
            "Brett A. Howell, Hamner Institutes for Health Sciences"
        ],
        "published": "July 21, 2014",
        "recorded": "May 2014",
        "category": [
            "Top->Medicine"
        ]
    },
    "url": "http://videolectures.net/mdo2014_howell_hepatotoxicity/",
    "segmentation": [
        [
            "Thank you to the organizers for the invitation to share some of our work, and also for all of you for attending.",
            "This is the Hamner Institutes in the southern US, where I come from and you have to forgive me for my Southern US accent as well throughout the talk."
        ],
        [
            "This work is a product of the daily some initiative.",
            "This is a consortium of the companies that you see here on the screen with the sole focus of supporting the development of the daily SIM software and this is a hopefully predictive mathematical mechanistic modeling tool that is meant to predict and shed light on drug induced liver injury, which is a major problem for many of these companies.",
            "And the overall goals are to ultimately improve patient safety and reduce the cost.",
            "Of course associated with developing drugs.",
            "And the companies not only support the work that I'm going to share in our team, but they also guide us in terms of what we do.",
            "They actually have voting, annual voting meetings and determine exactly what the objectives are.",
            "So this is."
        ],
        [
            "Our team, Paul Watkins, is the director and chair of the consortium and and also like to always like to think the Scientific Advisory Board.",
            "These are the members of the board who provide us with scientific guidance and oversight and ensure that we're focusing on the key issues in terms of the science as well, and they have a large array of areas of specialty.",
            "Of course, liver being one of the key ones, but also influences from regulatory agencies an adaptive immunity in other areas that are critical for this effort."
        ],
        [
            "So the goals of the of the daily, some initiative, that consortium stage one goals focused on, and that would be the last three years, and we're in the final state final year of stage one.",
            "Really, the goal was to develop a tool modeling tool that would allow us to take in vitro data focused on Apache toxicity and drug exposure, and predict or understand potential drug induced liver injury in a variety of species and so to focus sort of vitro stage, and then extrapolating preclinical data to 1st in man studies.",
            "And the types of data that can be used, like as I said we in vitro data, but also early clinical data and preclinical data.",
            "So Dilly stem state stage two is more than likely going to be focused on actually moving from these this phase one or a pre clinical prediction space to larger clinical trials and with the ultimate goal long term of companies being able to have a better sense of the possibility for rare drug induced liver injury events early in drug development and not at the end of drug development when the drug is already on the market.",
            "And this is really the key issue for these companies.",
            "So practically, what do you do with with daily?",
            "Simply put in data so it can be data related to the exposure and also the toxic dynamics of the drug, the potential mechanisms, and then you simulate drug exposures.",
            "The health of the parasites including the ATP, glutathione levels and other metrics, as well as the bio, cell death and biomarker outputs.",
            "Overtime, all of those things overtime, and also of course across dose for a variety of species.",
            "An goes again to help enhance the understanding of what's contributing to observe liver signals, particularly in clinical trials when questions arise about benefit versus risk."
        ],
        [
            "So just to give an overview of our approach, I would say that you know.",
            "It relative to the earlier talk that was given.",
            "This Is Us really a systems pharmacology approach or system toxicology.",
            "I guess we more like it and this review figures really shows, I think, nicely the various scales that are used in general in mechanistic modeling and illicium focuses on starting at the liver, and so something like to cellular life cycle of liver cells as they move from the young state to the mature state and into a state of ptosis or necrosis that is sort of the key key scale for dilly SIM.",
            "But we also have sub cellular components or compartments.",
            "Like mitochondrial dysfunction, where we focus on individual complexes when necessary and we also have organ whole body submodels that also predict exposure, such as a PPK portion.",
            "And we vary the parameters associated with many of these submodels to give us variability in response which is really critical for something like drug induced liver injury, which tends to occur at a very low frequency.",
            "So what you see here on the bottom right is in blue or these data points are.",
            "The average and deviations around the average for liver enzymes that have leaked out of people who have had severe liver injury due to a paracetamol or acetaminophen overdose, and they presented to the clinic and so with Billy SIM the average human, so to speak in Dillon would be represented by sort of the curve that goes through the middle of those points, but you can see that by varying parameters associated with some of the sub models in the pharmacokinetics, we can produce simulated responders and nonresponders, and then we can try to understand why they're responding in that way."
        ],
        [
            "So just to give you an overview of a few snapshots of what's included in Dilley.",
            "Some we have mouse, rat, dog and human as the species of focus.",
            "There's been discussion of monkey, but we haven't moved in that direction yet, as it's sort of a middle out or a again a system pharmacology approach.",
            "The scale of the liver actually provides an example of the level of detail, so the liver in Delhi some includes three compartments.",
            "It doesn't have a continuous asinas representation.",
            "With partial differential equations, but it does have three different distinct zones, and so there's some level of detail there.",
            "The level of detail that was deemed necessary, but it's not extremely detailed in in that way.",
            "And this figure shows some of the processes that are included, so we have ranging all the way from drug metabolism distribution to things like reactive tablets, bile acids and mitochondrial dysfunction, and ultimately leading to the to biomarkers.",
            "And it's important to note that that it was designed in this way so that it could actually speak to clinicians.",
            "Anbia clinical tool.",
            "Ultimately, in the end, so it does have outputs and biomarkers that that clinicians are used to seeing, and even preclinical tox folks are used to seeing.",
            "So again."
        ],
        [
            "What are the inputs that that go into tillessen?",
            "Well, as you'd imagine, they focus on the admin processes, of course, because we need to get as good as possible an estimation of the contradiction of the concentration of the drug and metabolites in the liver.",
            "And there are also a number of inputs that focus on sort of the mechanistic toxicology top.",
            "Sorry toxicokinetics of the model, and so some of those are listed here, so they would.",
            "Those would be things like inhibition constants that tell you the strength of inhibition of a particular transporter by drug indicators for oxidative stress and or ATP depletion, and then also clinical biomarker outcomes when we can get them that indicate a certain mode of cell death versus another.",
            "So those would all be inputs and in terms of outputs we have.",
            "Of course we have some that are not so clinical in that we can look at the actual number of parasites that are viable in the liver at any given point over the course of a simulation.",
            "We can look at ATP and these other things in terms of clinical we have your typical liver enzyme outputs, prothrombin time, bilirubin in these types of biomarkers.",
            "We've also incorporated some of the newer ones that are probably being discussed in our parallel session such as HMG, One and Cytokeratin 18 different markers that are meant to actually start to tell you what's going on inside the liver and not just that delivers.",
            "In trouble.",
            "So there are a number of things."
        ],
        [
            "Is that you can practically tangibly do with a tool like this, and we've worked in a number of these things and published some papers on them.",
            "I'm going to highlight a couple of key examples really quickly and just give an overview of of a couple of examples.",
            "So the first is really focused on a very simple clinical biomarker analysis, and this is not an example where a lot of data was put into the model and a prediction was made.",
            "This is actually one where the biomarker signatures that came out in a clinical trial were used.",
            "To try and understand what was happening in the liver, so it was sort of a retrospective view of the situation without a lot of mechanistic information."
        ],
        [
            "So this is a scenario.",
            "There's a company, Cleveland Bio Labs.",
            "They have a drug in development.",
            "It's called Entolimod and it reduces radiation mortality by up to 40% for severe radiation.",
            "So the circumstances that maybe there's a nuclear meltdown for a nuclear reactor or a dirty bomb goes off in a very large city an you have these individuals coming in a helicopter and shooting all of us with this drug and hopefully saving about 40 out of every 100 who would otherwise die from lethal radiation.",
            "So the obvious, there's obviously a number of governments that have an interest in having something like this stockpiled, and actually it satisfies the FDA's animal rule and the animal rule says that if you can show efficacy in two animal species in a situation where it's very difficult or impossible to conduct human trials, the drug can be approved and this drug has been shown to be efficacious in more than two animal species.",
            "But the problem is the animal rule does not cover safety concerns, and so in an early safety study, some clinical.",
            "Some Lt liver signals were observed from AST signals and the question was is this?",
            "What's the benefit versus the risk in this case?",
            "So the objective with Dilley said was for us to infer the amount of the parasite necrosis that was necessary to lead to the biomarker results that they saw in the trials and help the company understand what was actually going on inside the liver.",
            "So in this case."
        ],
        [
            "The focus was only focused on humans first of all, and also only was a connection between the parasite life cycle and the biomarkers.",
            "In this in dilution, so it didn't focus on PK or any of the upstream, or even the mechanistic components."
        ],
        [
            "So this is some of the clinical data that we were provided and what you see here is on the Y axis.",
            "Is liver enzyme levels which indicate cell death or loss of hepatocytes, and on the X axis you see the time course.",
            "And so we see that for a lot of these individuals there was no response.",
            "But for a few there was a pretty significant response.",
            "And just to simplify, it was focus on the Max and the 95th percentile in the median.",
            "So when you see an Lt elevation that reaches 1000, this is definitely a concern for regulatory.",
            "Authority and the question that they have is what does this actually mean?",
            "And if you draw your attention to the kinetics of the profile of these Lt elevations.",
            "This was a rapid increase of altti and actually fill it.",
            "Basically the half life of a Lt.",
            "So this is very very different than what you see with a Lt in most clinical trials in most trials or even with something like acetaminophen.",
            "It takes several days to CLT, come up and it takes several weeks or days or even months to go away.",
            "So this is actually a fairly unique case.",
            "There, I think modeling lends itself to being quite useful, so we went into daily SIM and induced necrosis and simulated human.",
            "And and tried our best to match the biomarker signatures that they saw.",
            "And then we ask the question what was happening in the liver to give you those Lt elevations and what you see here is that for the predicted Max level of a Lt we predicted 3 1/2% loss of the viable hepatocytes in the liver as the Max as the Max loss.",
            "But we all know that predicting for an average human we none of us are average, so we wanted to then look at what's the variability around that prediction.",
            "And this was."
        ],
        [
            "So the key figure for the project so you see on the on the on the Y axis that predicted loss of liver and on the X axis various observed peak bins.",
            "If you will arrange is so for the maximum range that they saw up around 1000, we predicted a range of anywhere from 2 to 5%.",
            "Loss of the liver, and so we made this population based prediction by varying the parameters that are associated with Lt.",
            "So things like the amount of Lt that all of us contain in each of our hepatocytes.",
            "In the half-life for clearance, frailty and other parameters that we could take from the literature.",
            "So we."
        ],
        [
            "I want to do a number of additional things for this project.",
            "As I said, we predicted 5% or less loss of liver.",
            "We also predicted a regeneration time for the liver of approximately 3 weeks for the median individual we went to do some modeling on Heparin Zan.",
            "Look at literature that ultimately led us to the end to power Director to the conclusion that these were probably trivial levels of liver loss relative to the benefit of the drug, so these results were then submitted to the FDA in support.",
            "Of the safety of the drug, along with a number of other pieces of data that were both related and unrelated to the liver."
        ],
        [
            "So that's sort of a niche use of daily send, focused on biomarker analysis.",
            "The second example is actually more what I would say more intuitive approach, which is where you put in a number of pieces of data or information into delete him and try to predict what's going to happen in a clinical trial."
        ],
        [
            "I left this sort background here just to make sure that I give credit to Kyung Hee Yang.",
            "She's actually joining us, joining us today.",
            "Actually as a postdoc, but was doing her defense and dissertation in collaboration with us over the last couple of years, so this was largely her work, focused on triplet his own."
        ],
        [
            "So chocolate is on was a very first in class.",
            "PPR gamma agonist that was very effective at treating diabetes.",
            "An was thought to be a very a potential, potentially a blockbuster drug.",
            "However, it is now become the poster child for rare, idiosyncratic, unforeseen serious Patty toxicity.",
            "And So what are the mechanisms of para toxicity?",
            "Witcher Glitazone a number of mechanisms have been proposed.",
            "Probably one of the most well lucid elucidated mechanisms would be the impairment of bile acid transport, and so this was the focus of killing his work.",
            "She comes from Doctor Kim Brauers lab at UNC University of North Carolina in the States an.",
            "Their labs focuses heavily in this area, so it was a natural fit for her.",
            "So she did both a number of experimental analysis, but also the daily some workers.",
            "Part of her project so."
        ],
        [
            "Again, if you compare this with the previous example, there's really a focus here on the full scope of delissen from PK all the way to outcomes."
        ],
        [
            "And the idea behind modelling Troglitazone as a as an impact as something that impairs bile acid transport is that we know bile acids are taken up by uptake transporters and then E flux into the bile into the blood.",
            "And chocolate is own is taken up by the liver and is metabolised largely to trickle in sulfate.",
            "In this software has been shown in vitro to block a number of efflux transporters from bile acids, and you could extrapolate that as to think that potentially a buildup of those bile acids cause toxicity.",
            "But the question is, how do you bring all of these parameters together in one framework to try and understand the true implications for that mechanism versus other potential mechanisms?"
        ],
        [
            "So can he did that with Allison?",
            "In this way she started by developing a PPK model for trigger, his own she then.",
            "Worked with us as we establish the bile acid homeostasis submodel of daily SIM and that was connected through some in vitro work that her lab did in Kim's lab, did to actually the levels of cellular ATP that result when the liver is exposed to very high levels of bile acids.",
            "So you can go from PK all the way to the effect on the parasites and ultimately to biomarkers.",
            "So she constructed this framework.",
            "She also varied several of the parameters related to the pharmacokinetics of circular zone, as well as related to some of the underlying biology associated with bile, acid transport and synthesis to create population of individuals."
        ],
        [
            "And then she simulated through his own one of the early triggers on clinical trials.",
            "So she put in the in vitro data and she put in her PK model and ran a simulation.",
            "And what we see here are the results.",
            "So you have three different doses of triggered his own that are clinically relevant.",
            "We see that Maxima Lt is on the Y axis and there were 331 simulated individuals in this trial.",
            "So what we see are at 200 milligrams.",
            "That was largely no response even with treatment for six months.",
            "But as you went to two 400 and 600 milligrams, we started to see responders."
        ],
        [
            "And so we can compare that in a more tabular fashion with what was seen in the clinical trial for trigger zone.",
            "So the clinical trial results are on the right, and these were reported.",
            "And then on the left we see the simulation results at 400 and 600 milligrams.",
            "And we were fairly surprised.",
            "And also I guess I would say pleasantly surprised to see that the predictions for attribute his own and the Lt elevation incidence rates were very similar to what was seen in the clinical trials.",
            "If you look at the cases for jaundice they reported to they did not report an exact bilirubin, so it was hard to compare the exact bilirubin.",
            "But we also saw several cases of jaundice, and that's probably 1 area where we're over predicting.",
            "One of the things that was done.",
            "Was she simulated this for six months without stopping, despite the fact that the Lt was going up which clinically you would stop?",
            "So we're now going back to simulate this with a dynamic protocol that actually checks within this simulation to see if the patient needs to be stopped in terms of their dosing."
        ],
        [
            "But this was very encouraging for us and we can take this to the next step and say, what are these responders look like overtime?",
            "So this shows the liver enzyme elevation profiles for these responders over a period of six months.",
            "And what you see is that for some of these individuals, Lt was going up very quickly, for others it was coming on pretty late.",
            "And actually the time to peak was in the neighborhood of what was seen clinically.",
            "So there's certainly differences between what was observed.",
            "Our model is not predicting the severe life threatening situation that a curd for some individuals later, after they saw this initial incidents, our initial elevation, but this was encouraging, I think, and also to the consortium that long term this tool could be helpful for them prospectively."
        ],
        [
            "So can he also went and looked at all of the variables that were adjusted for this population and altered and varied and she found the ones that were most important or correlated in a multiple regression most closely with outcome.",
            "So these were some of the things in black that fell out of that.",
            "So some of these, like the clearance of triggers on sulfate, is very intuitive.",
            "But then others like LCA synthesis in the intestinal lumen was less intuitive.",
            "So I think this is just a good good example of how modeling tools can lead you to hypothesis.",
            "That you then go back into Jiwa's or some sort of genetic analysis an use these as your hypothesis and increase your statistical power potentially."
        ],
        [
            "And one final note, I don't have alot of time to talk about the rat, but can he also did this in the rat and this shows the Lt elevations in the rat were largely absent, which is what was seen preclinically as well.",
            "An interesting Lee.",
            "This was not a PK effect, so here we see troglitazone sulfate in liver is actually higher for the rat, so it's actually a biological effect, so we see in this plot shown at the bottom here that the most toxic bile acid species, CDC and LCA, are far lower in prevalence in the rat compared to the human.",
            "So this was, and in this particular case, variability between species that fell out of the TV or the PD, if you will, and not the the PK."
        ],
        [
            "So just in conclusion, triggers on pad toxicity, or at least the ALT elevations observed or predicted.",
            "The modeling incorporated sort of the species differences and predicted those species differences based on fundamental biological concepts that have been built into the model, such as the bile acid profile.",
            "And finally, we think that long term you could take in vitro data.",
            "You take preclinical PK or clinical PK, put into an approach like this and at least get an early idea of what might happen in clinical trials.",
            "As you make decisions about developing drugs so."
        ],
        [
            "To acknowledge Cleveland Biolabs for their gracious sponsorship of the work and they're allowing us to present these materials.",
            "Of course, the Delisa members in their sponsorship and also can he for her work on this project as part of her defense and dissertation.",
            "So with that, I'll take any questions.",
            "I wonder in in your model for the set on the life cycle for the liver you eat.",
            "You also include CKD and rhythms.",
            "We have not included circadian rhythms to this point.",
            "We've started to include or.",
            "We do include the feeding patterns across the different species and how those will affect things like mitochondrial function.",
            "But the circadian rhythms are sort of on the To Do List and need to need to be incorporated for sure.",
            "OK. Are there any more questions?",
            "I would like to take another one and I'm coming from industry.",
            "I think I have to ask this and this.",
            "This is some software business before free or will it be commercially available?",
            "It's a good question.",
            "It's currently the way that the consortium works is the the partners, the members of the consortium are the only ones that receive daily said.",
            "Currently the current time.",
            "But we are working through the process of creating an academic version of deletions so that we can disseminate, disseminate it more widely and have it used by academics and regulators and others.",
            "You know to sort of test drive it and see, and also check the concepts and things like that.",
            "So OK in the works I would say.",
            "Thank you."
        ]
    ],
    "summarization": {
        "clip_0": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Thank you to the organizers for the invitation to share some of our work, and also for all of you for attending.",
                    "label": 0
                },
                {
                    "sent": "This is the Hamner Institutes in the southern US, where I come from and you have to forgive me for my Southern US accent as well throughout the talk.",
                    "label": 0
                }
            ]
        },
        "clip_1": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "This work is a product of the daily some initiative.",
                    "label": 1
                },
                {
                    "sent": "This is a consortium of the companies that you see here on the screen with the sole focus of supporting the development of the daily SIM software and this is a hopefully predictive mathematical mechanistic modeling tool that is meant to predict and shed light on drug induced liver injury, which is a major problem for many of these companies.",
                    "label": 0
                },
                {
                    "sent": "And the overall goals are to ultimately improve patient safety and reduce the cost.",
                    "label": 1
                },
                {
                    "sent": "Of course associated with developing drugs.",
                    "label": 0
                },
                {
                    "sent": "And the companies not only support the work that I'm going to share in our team, but they also guide us in terms of what we do.",
                    "label": 0
                },
                {
                    "sent": "They actually have voting, annual voting meetings and determine exactly what the objectives are.",
                    "label": 0
                },
                {
                    "sent": "So this is.",
                    "label": 0
                }
            ]
        },
        "clip_2": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Our team, Paul Watkins, is the director and chair of the consortium and and also like to always like to think the Scientific Advisory Board.",
                    "label": 0
                },
                {
                    "sent": "These are the members of the board who provide us with scientific guidance and oversight and ensure that we're focusing on the key issues in terms of the science as well, and they have a large array of areas of specialty.",
                    "label": 0
                },
                {
                    "sent": "Of course, liver being one of the key ones, but also influences from regulatory agencies an adaptive immunity in other areas that are critical for this effort.",
                    "label": 0
                }
            ]
        },
        "clip_3": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So the goals of the of the daily, some initiative, that consortium stage one goals focused on, and that would be the last three years, and we're in the final state final year of stage one.",
                    "label": 0
                },
                {
                    "sent": "Really, the goal was to develop a tool modeling tool that would allow us to take in vitro data focused on Apache toxicity and drug exposure, and predict or understand potential drug induced liver injury in a variety of species and so to focus sort of vitro stage, and then extrapolating preclinical data to 1st in man studies.",
                    "label": 0
                },
                {
                    "sent": "And the types of data that can be used, like as I said we in vitro data, but also early clinical data and preclinical data.",
                    "label": 1
                },
                {
                    "sent": "So Dilly stem state stage two is more than likely going to be focused on actually moving from these this phase one or a pre clinical prediction space to larger clinical trials and with the ultimate goal long term of companies being able to have a better sense of the possibility for rare drug induced liver injury events early in drug development and not at the end of drug development when the drug is already on the market.",
                    "label": 0
                },
                {
                    "sent": "And this is really the key issue for these companies.",
                    "label": 0
                },
                {
                    "sent": "So practically, what do you do with with daily?",
                    "label": 0
                },
                {
                    "sent": "Simply put in data so it can be data related to the exposure and also the toxic dynamics of the drug, the potential mechanisms, and then you simulate drug exposures.",
                    "label": 0
                },
                {
                    "sent": "The health of the parasites including the ATP, glutathione levels and other metrics, as well as the bio, cell death and biomarker outputs.",
                    "label": 0
                },
                {
                    "sent": "Overtime, all of those things overtime, and also of course across dose for a variety of species.",
                    "label": 0
                },
                {
                    "sent": "An goes again to help enhance the understanding of what's contributing to observe liver signals, particularly in clinical trials when questions arise about benefit versus risk.",
                    "label": 1
                }
            ]
        },
        "clip_4": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So just to give an overview of our approach, I would say that you know.",
                    "label": 0
                },
                {
                    "sent": "It relative to the earlier talk that was given.",
                    "label": 0
                },
                {
                    "sent": "This Is Us really a systems pharmacology approach or system toxicology.",
                    "label": 0
                },
                {
                    "sent": "I guess we more like it and this review figures really shows, I think, nicely the various scales that are used in general in mechanistic modeling and illicium focuses on starting at the liver, and so something like to cellular life cycle of liver cells as they move from the young state to the mature state and into a state of ptosis or necrosis that is sort of the key key scale for dilly SIM.",
                    "label": 0
                },
                {
                    "sent": "But we also have sub cellular components or compartments.",
                    "label": 0
                },
                {
                    "sent": "Like mitochondrial dysfunction, where we focus on individual complexes when necessary and we also have organ whole body submodels that also predict exposure, such as a PPK portion.",
                    "label": 0
                },
                {
                    "sent": "And we vary the parameters associated with many of these submodels to give us variability in response which is really critical for something like drug induced liver injury, which tends to occur at a very low frequency.",
                    "label": 0
                },
                {
                    "sent": "So what you see here on the bottom right is in blue or these data points are.",
                    "label": 0
                },
                {
                    "sent": "The average and deviations around the average for liver enzymes that have leaked out of people who have had severe liver injury due to a paracetamol or acetaminophen overdose, and they presented to the clinic and so with Billy SIM the average human, so to speak in Dillon would be represented by sort of the curve that goes through the middle of those points, but you can see that by varying parameters associated with some of the sub models in the pharmacokinetics, we can produce simulated responders and nonresponders, and then we can try to understand why they're responding in that way.",
                    "label": 0
                }
            ]
        },
        "clip_5": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So just to give you an overview of a few snapshots of what's included in Dilley.",
                    "label": 0
                },
                {
                    "sent": "Some we have mouse, rat, dog and human as the species of focus.",
                    "label": 0
                },
                {
                    "sent": "There's been discussion of monkey, but we haven't moved in that direction yet, as it's sort of a middle out or a again a system pharmacology approach.",
                    "label": 0
                },
                {
                    "sent": "The scale of the liver actually provides an example of the level of detail, so the liver in Delhi some includes three compartments.",
                    "label": 0
                },
                {
                    "sent": "It doesn't have a continuous asinas representation.",
                    "label": 0
                },
                {
                    "sent": "With partial differential equations, but it does have three different distinct zones, and so there's some level of detail there.",
                    "label": 0
                },
                {
                    "sent": "The level of detail that was deemed necessary, but it's not extremely detailed in in that way.",
                    "label": 0
                },
                {
                    "sent": "And this figure shows some of the processes that are included, so we have ranging all the way from drug metabolism distribution to things like reactive tablets, bile acids and mitochondrial dysfunction, and ultimately leading to the to biomarkers.",
                    "label": 0
                },
                {
                    "sent": "And it's important to note that that it was designed in this way so that it could actually speak to clinicians.",
                    "label": 0
                },
                {
                    "sent": "Anbia clinical tool.",
                    "label": 0
                },
                {
                    "sent": "Ultimately, in the end, so it does have outputs and biomarkers that that clinicians are used to seeing, and even preclinical tox folks are used to seeing.",
                    "label": 0
                },
                {
                    "sent": "So again.",
                    "label": 0
                }
            ]
        },
        "clip_6": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "What are the inputs that that go into tillessen?",
                    "label": 0
                },
                {
                    "sent": "Well, as you'd imagine, they focus on the admin processes, of course, because we need to get as good as possible an estimation of the contradiction of the concentration of the drug and metabolites in the liver.",
                    "label": 0
                },
                {
                    "sent": "And there are also a number of inputs that focus on sort of the mechanistic toxicology top.",
                    "label": 0
                },
                {
                    "sent": "Sorry toxicokinetics of the model, and so some of those are listed here, so they would.",
                    "label": 0
                },
                {
                    "sent": "Those would be things like inhibition constants that tell you the strength of inhibition of a particular transporter by drug indicators for oxidative stress and or ATP depletion, and then also clinical biomarker outcomes when we can get them that indicate a certain mode of cell death versus another.",
                    "label": 0
                },
                {
                    "sent": "So those would all be inputs and in terms of outputs we have.",
                    "label": 0
                },
                {
                    "sent": "Of course we have some that are not so clinical in that we can look at the actual number of parasites that are viable in the liver at any given point over the course of a simulation.",
                    "label": 0
                },
                {
                    "sent": "We can look at ATP and these other things in terms of clinical we have your typical liver enzyme outputs, prothrombin time, bilirubin in these types of biomarkers.",
                    "label": 0
                },
                {
                    "sent": "We've also incorporated some of the newer ones that are probably being discussed in our parallel session such as HMG, One and Cytokeratin 18 different markers that are meant to actually start to tell you what's going on inside the liver and not just that delivers.",
                    "label": 0
                },
                {
                    "sent": "In trouble.",
                    "label": 0
                },
                {
                    "sent": "So there are a number of things.",
                    "label": 0
                }
            ]
        },
        "clip_7": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Is that you can practically tangibly do with a tool like this, and we've worked in a number of these things and published some papers on them.",
                    "label": 0
                },
                {
                    "sent": "I'm going to highlight a couple of key examples really quickly and just give an overview of of a couple of examples.",
                    "label": 0
                },
                {
                    "sent": "So the first is really focused on a very simple clinical biomarker analysis, and this is not an example where a lot of data was put into the model and a prediction was made.",
                    "label": 0
                },
                {
                    "sent": "This is actually one where the biomarker signatures that came out in a clinical trial were used.",
                    "label": 0
                },
                {
                    "sent": "To try and understand what was happening in the liver, so it was sort of a retrospective view of the situation without a lot of mechanistic information.",
                    "label": 0
                }
            ]
        },
        "clip_8": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So this is a scenario.",
                    "label": 0
                },
                {
                    "sent": "There's a company, Cleveland Bio Labs.",
                    "label": 0
                },
                {
                    "sent": "They have a drug in development.",
                    "label": 0
                },
                {
                    "sent": "It's called Entolimod and it reduces radiation mortality by up to 40% for severe radiation.",
                    "label": 1
                },
                {
                    "sent": "So the circumstances that maybe there's a nuclear meltdown for a nuclear reactor or a dirty bomb goes off in a very large city an you have these individuals coming in a helicopter and shooting all of us with this drug and hopefully saving about 40 out of every 100 who would otherwise die from lethal radiation.",
                    "label": 0
                },
                {
                    "sent": "So the obvious, there's obviously a number of governments that have an interest in having something like this stockpiled, and actually it satisfies the FDA's animal rule and the animal rule says that if you can show efficacy in two animal species in a situation where it's very difficult or impossible to conduct human trials, the drug can be approved and this drug has been shown to be efficacious in more than two animal species.",
                    "label": 1
                },
                {
                    "sent": "But the problem is the animal rule does not cover safety concerns, and so in an early safety study, some clinical.",
                    "label": 0
                },
                {
                    "sent": "Some Lt liver signals were observed from AST signals and the question was is this?",
                    "label": 0
                },
                {
                    "sent": "What's the benefit versus the risk in this case?",
                    "label": 0
                },
                {
                    "sent": "So the objective with Dilley said was for us to infer the amount of the parasite necrosis that was necessary to lead to the biomarker results that they saw in the trials and help the company understand what was actually going on inside the liver.",
                    "label": 1
                },
                {
                    "sent": "So in this case.",
                    "label": 0
                }
            ]
        },
        "clip_9": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "The focus was only focused on humans first of all, and also only was a connection between the parasite life cycle and the biomarkers.",
                    "label": 0
                },
                {
                    "sent": "In this in dilution, so it didn't focus on PK or any of the upstream, or even the mechanistic components.",
                    "label": 0
                }
            ]
        },
        "clip_10": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So this is some of the clinical data that we were provided and what you see here is on the Y axis.",
                    "label": 0
                },
                {
                    "sent": "Is liver enzyme levels which indicate cell death or loss of hepatocytes, and on the X axis you see the time course.",
                    "label": 0
                },
                {
                    "sent": "And so we see that for a lot of these individuals there was no response.",
                    "label": 0
                },
                {
                    "sent": "But for a few there was a pretty significant response.",
                    "label": 0
                },
                {
                    "sent": "And just to simplify, it was focus on the Max and the 95th percentile in the median.",
                    "label": 0
                },
                {
                    "sent": "So when you see an Lt elevation that reaches 1000, this is definitely a concern for regulatory.",
                    "label": 0
                },
                {
                    "sent": "Authority and the question that they have is what does this actually mean?",
                    "label": 0
                },
                {
                    "sent": "And if you draw your attention to the kinetics of the profile of these Lt elevations.",
                    "label": 0
                },
                {
                    "sent": "This was a rapid increase of altti and actually fill it.",
                    "label": 0
                },
                {
                    "sent": "Basically the half life of a Lt.",
                    "label": 0
                },
                {
                    "sent": "So this is very very different than what you see with a Lt in most clinical trials in most trials or even with something like acetaminophen.",
                    "label": 0
                },
                {
                    "sent": "It takes several days to CLT, come up and it takes several weeks or days or even months to go away.",
                    "label": 0
                },
                {
                    "sent": "So this is actually a fairly unique case.",
                    "label": 0
                },
                {
                    "sent": "There, I think modeling lends itself to being quite useful, so we went into daily SIM and induced necrosis and simulated human.",
                    "label": 0
                },
                {
                    "sent": "And and tried our best to match the biomarker signatures that they saw.",
                    "label": 0
                },
                {
                    "sent": "And then we ask the question what was happening in the liver to give you those Lt elevations and what you see here is that for the predicted Max level of a Lt we predicted 3 1/2% loss of the viable hepatocytes in the liver as the Max as the Max loss.",
                    "label": 0
                },
                {
                    "sent": "But we all know that predicting for an average human we none of us are average, so we wanted to then look at what's the variability around that prediction.",
                    "label": 0
                },
                {
                    "sent": "And this was.",
                    "label": 0
                }
            ]
        },
        "clip_11": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So the key figure for the project so you see on the on the on the Y axis that predicted loss of liver and on the X axis various observed peak bins.",
                    "label": 0
                },
                {
                    "sent": "If you will arrange is so for the maximum range that they saw up around 1000, we predicted a range of anywhere from 2 to 5%.",
                    "label": 0
                },
                {
                    "sent": "Loss of the liver, and so we made this population based prediction by varying the parameters that are associated with Lt.",
                    "label": 0
                },
                {
                    "sent": "So things like the amount of Lt that all of us contain in each of our hepatocytes.",
                    "label": 0
                },
                {
                    "sent": "In the half-life for clearance, frailty and other parameters that we could take from the literature.",
                    "label": 0
                },
                {
                    "sent": "So we.",
                    "label": 0
                }
            ]
        },
        "clip_12": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "I want to do a number of additional things for this project.",
                    "label": 0
                },
                {
                    "sent": "As I said, we predicted 5% or less loss of liver.",
                    "label": 0
                },
                {
                    "sent": "We also predicted a regeneration time for the liver of approximately 3 weeks for the median individual we went to do some modeling on Heparin Zan.",
                    "label": 0
                },
                {
                    "sent": "Look at literature that ultimately led us to the end to power Director to the conclusion that these were probably trivial levels of liver loss relative to the benefit of the drug, so these results were then submitted to the FDA in support.",
                    "label": 1
                },
                {
                    "sent": "Of the safety of the drug, along with a number of other pieces of data that were both related and unrelated to the liver.",
                    "label": 0
                }
            ]
        },
        "clip_13": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So that's sort of a niche use of daily send, focused on biomarker analysis.",
                    "label": 0
                },
                {
                    "sent": "The second example is actually more what I would say more intuitive approach, which is where you put in a number of pieces of data or information into delete him and try to predict what's going to happen in a clinical trial.",
                    "label": 0
                }
            ]
        },
        "clip_14": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "I left this sort background here just to make sure that I give credit to Kyung Hee Yang.",
                    "label": 0
                },
                {
                    "sent": "She's actually joining us, joining us today.",
                    "label": 0
                },
                {
                    "sent": "Actually as a postdoc, but was doing her defense and dissertation in collaboration with us over the last couple of years, so this was largely her work, focused on triplet his own.",
                    "label": 0
                }
            ]
        },
        "clip_15": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So chocolate is on was a very first in class.",
                    "label": 1
                },
                {
                    "sent": "PPR gamma agonist that was very effective at treating diabetes.",
                    "label": 0
                },
                {
                    "sent": "An was thought to be a very a potential, potentially a blockbuster drug.",
                    "label": 0
                },
                {
                    "sent": "However, it is now become the poster child for rare, idiosyncratic, unforeseen serious Patty toxicity.",
                    "label": 0
                },
                {
                    "sent": "And So what are the mechanisms of para toxicity?",
                    "label": 1
                },
                {
                    "sent": "Witcher Glitazone a number of mechanisms have been proposed.",
                    "label": 0
                },
                {
                    "sent": "Probably one of the most well lucid elucidated mechanisms would be the impairment of bile acid transport, and so this was the focus of killing his work.",
                    "label": 1
                },
                {
                    "sent": "She comes from Doctor Kim Brauers lab at UNC University of North Carolina in the States an.",
                    "label": 0
                },
                {
                    "sent": "Their labs focuses heavily in this area, so it was a natural fit for her.",
                    "label": 0
                },
                {
                    "sent": "So she did both a number of experimental analysis, but also the daily some workers.",
                    "label": 0
                },
                {
                    "sent": "Part of her project so.",
                    "label": 0
                }
            ]
        },
        "clip_16": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Again, if you compare this with the previous example, there's really a focus here on the full scope of delissen from PK all the way to outcomes.",
                    "label": 0
                }
            ]
        },
        "clip_17": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "And the idea behind modelling Troglitazone as a as an impact as something that impairs bile acid transport is that we know bile acids are taken up by uptake transporters and then E flux into the bile into the blood.",
                    "label": 0
                },
                {
                    "sent": "And chocolate is own is taken up by the liver and is metabolised largely to trickle in sulfate.",
                    "label": 0
                },
                {
                    "sent": "In this software has been shown in vitro to block a number of efflux transporters from bile acids, and you could extrapolate that as to think that potentially a buildup of those bile acids cause toxicity.",
                    "label": 0
                },
                {
                    "sent": "But the question is, how do you bring all of these parameters together in one framework to try and understand the true implications for that mechanism versus other potential mechanisms?",
                    "label": 0
                }
            ]
        },
        "clip_18": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So can he did that with Allison?",
                    "label": 0
                },
                {
                    "sent": "In this way she started by developing a PPK model for trigger, his own she then.",
                    "label": 0
                },
                {
                    "sent": "Worked with us as we establish the bile acid homeostasis submodel of daily SIM and that was connected through some in vitro work that her lab did in Kim's lab, did to actually the levels of cellular ATP that result when the liver is exposed to very high levels of bile acids.",
                    "label": 0
                },
                {
                    "sent": "So you can go from PK all the way to the effect on the parasites and ultimately to biomarkers.",
                    "label": 0
                },
                {
                    "sent": "So she constructed this framework.",
                    "label": 0
                },
                {
                    "sent": "She also varied several of the parameters related to the pharmacokinetics of circular zone, as well as related to some of the underlying biology associated with bile, acid transport and synthesis to create population of individuals.",
                    "label": 0
                }
            ]
        },
        "clip_19": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "And then she simulated through his own one of the early triggers on clinical trials.",
                    "label": 0
                },
                {
                    "sent": "So she put in the in vitro data and she put in her PK model and ran a simulation.",
                    "label": 0
                },
                {
                    "sent": "And what we see here are the results.",
                    "label": 0
                },
                {
                    "sent": "So you have three different doses of triggered his own that are clinically relevant.",
                    "label": 0
                },
                {
                    "sent": "We see that Maxima Lt is on the Y axis and there were 331 simulated individuals in this trial.",
                    "label": 0
                },
                {
                    "sent": "So what we see are at 200 milligrams.",
                    "label": 0
                },
                {
                    "sent": "That was largely no response even with treatment for six months.",
                    "label": 0
                },
                {
                    "sent": "But as you went to two 400 and 600 milligrams, we started to see responders.",
                    "label": 0
                }
            ]
        },
        "clip_20": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "And so we can compare that in a more tabular fashion with what was seen in the clinical trial for trigger zone.",
                    "label": 0
                },
                {
                    "sent": "So the clinical trial results are on the right, and these were reported.",
                    "label": 0
                },
                {
                    "sent": "And then on the left we see the simulation results at 400 and 600 milligrams.",
                    "label": 0
                },
                {
                    "sent": "And we were fairly surprised.",
                    "label": 0
                },
                {
                    "sent": "And also I guess I would say pleasantly surprised to see that the predictions for attribute his own and the Lt elevation incidence rates were very similar to what was seen in the clinical trials.",
                    "label": 0
                },
                {
                    "sent": "If you look at the cases for jaundice they reported to they did not report an exact bilirubin, so it was hard to compare the exact bilirubin.",
                    "label": 0
                },
                {
                    "sent": "But we also saw several cases of jaundice, and that's probably 1 area where we're over predicting.",
                    "label": 0
                },
                {
                    "sent": "One of the things that was done.",
                    "label": 0
                },
                {
                    "sent": "Was she simulated this for six months without stopping, despite the fact that the Lt was going up which clinically you would stop?",
                    "label": 0
                },
                {
                    "sent": "So we're now going back to simulate this with a dynamic protocol that actually checks within this simulation to see if the patient needs to be stopped in terms of their dosing.",
                    "label": 0
                }
            ]
        },
        "clip_21": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "But this was very encouraging for us and we can take this to the next step and say, what are these responders look like overtime?",
                    "label": 0
                },
                {
                    "sent": "So this shows the liver enzyme elevation profiles for these responders over a period of six months.",
                    "label": 0
                },
                {
                    "sent": "And what you see is that for some of these individuals, Lt was going up very quickly, for others it was coming on pretty late.",
                    "label": 0
                },
                {
                    "sent": "And actually the time to peak was in the neighborhood of what was seen clinically.",
                    "label": 1
                },
                {
                    "sent": "So there's certainly differences between what was observed.",
                    "label": 0
                },
                {
                    "sent": "Our model is not predicting the severe life threatening situation that a curd for some individuals later, after they saw this initial incidents, our initial elevation, but this was encouraging, I think, and also to the consortium that long term this tool could be helpful for them prospectively.",
                    "label": 0
                }
            ]
        },
        "clip_22": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So can he also went and looked at all of the variables that were adjusted for this population and altered and varied and she found the ones that were most important or correlated in a multiple regression most closely with outcome.",
                    "label": 0
                },
                {
                    "sent": "So these were some of the things in black that fell out of that.",
                    "label": 0
                },
                {
                    "sent": "So some of these, like the clearance of triggers on sulfate, is very intuitive.",
                    "label": 0
                },
                {
                    "sent": "But then others like LCA synthesis in the intestinal lumen was less intuitive.",
                    "label": 1
                },
                {
                    "sent": "So I think this is just a good good example of how modeling tools can lead you to hypothesis.",
                    "label": 0
                },
                {
                    "sent": "That you then go back into Jiwa's or some sort of genetic analysis an use these as your hypothesis and increase your statistical power potentially.",
                    "label": 0
                }
            ]
        },
        "clip_23": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And one final note, I don't have alot of time to talk about the rat, but can he also did this in the rat and this shows the Lt elevations in the rat were largely absent, which is what was seen preclinically as well.",
                    "label": 0
                },
                {
                    "sent": "An interesting Lee.",
                    "label": 0
                },
                {
                    "sent": "This was not a PK effect, so here we see troglitazone sulfate in liver is actually higher for the rat, so it's actually a biological effect, so we see in this plot shown at the bottom here that the most toxic bile acid species, CDC and LCA, are far lower in prevalence in the rat compared to the human.",
                    "label": 1
                },
                {
                    "sent": "So this was, and in this particular case, variability between species that fell out of the TV or the PD, if you will, and not the the PK.",
                    "label": 0
                }
            ]
        },
        "clip_24": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So just in conclusion, triggers on pad toxicity, or at least the ALT elevations observed or predicted.",
                    "label": 0
                },
                {
                    "sent": "The modeling incorporated sort of the species differences and predicted those species differences based on fundamental biological concepts that have been built into the model, such as the bile acid profile.",
                    "label": 1
                },
                {
                    "sent": "And finally, we think that long term you could take in vitro data.",
                    "label": 0
                },
                {
                    "sent": "You take preclinical PK or clinical PK, put into an approach like this and at least get an early idea of what might happen in clinical trials.",
                    "label": 0
                },
                {
                    "sent": "As you make decisions about developing drugs so.",
                    "label": 0
                }
            ]
        },
        "clip_25": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "To acknowledge Cleveland Biolabs for their gracious sponsorship of the work and they're allowing us to present these materials.",
                    "label": 1
                },
                {
                    "sent": "Of course, the Delisa members in their sponsorship and also can he for her work on this project as part of her defense and dissertation.",
                    "label": 0
                },
                {
                    "sent": "So with that, I'll take any questions.",
                    "label": 0
                },
                {
                    "sent": "I wonder in in your model for the set on the life cycle for the liver you eat.",
                    "label": 0
                },
                {
                    "sent": "You also include CKD and rhythms.",
                    "label": 0
                },
                {
                    "sent": "We have not included circadian rhythms to this point.",
                    "label": 0
                },
                {
                    "sent": "We've started to include or.",
                    "label": 0
                },
                {
                    "sent": "We do include the feeding patterns across the different species and how those will affect things like mitochondrial function.",
                    "label": 0
                },
                {
                    "sent": "But the circadian rhythms are sort of on the To Do List and need to need to be incorporated for sure.",
                    "label": 0
                },
                {
                    "sent": "OK. Are there any more questions?",
                    "label": 0
                },
                {
                    "sent": "I would like to take another one and I'm coming from industry.",
                    "label": 0
                },
                {
                    "sent": "I think I have to ask this and this.",
                    "label": 0
                },
                {
                    "sent": "This is some software business before free or will it be commercially available?",
                    "label": 0
                },
                {
                    "sent": "It's a good question.",
                    "label": 0
                },
                {
                    "sent": "It's currently the way that the consortium works is the the partners, the members of the consortium are the only ones that receive daily said.",
                    "label": 0
                },
                {
                    "sent": "Currently the current time.",
                    "label": 0
                },
                {
                    "sent": "But we are working through the process of creating an academic version of deletions so that we can disseminate, disseminate it more widely and have it used by academics and regulators and others.",
                    "label": 0
                },
                {
                    "sent": "You know to sort of test drive it and see, and also check the concepts and things like that.",
                    "label": 0
                },
                {
                    "sent": "So OK in the works I would say.",
                    "label": 0
                },
                {
                    "sent": "Thank you.",
                    "label": 0
                }
            ]
        }
    }
}